ArticleAmerican journal of translational research2013
VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancer.
Article in American journal of translational research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 58 citations in OpenAlex.
- VCAM-1 as a common biomarker in inflammatory bowel disease and colorectal cancer: unveiling the dual anti-inflammatory and anti-cancer capacities of anti-VCAM-1 therapies.Cancer metastasis reviews · 2025Review
- SubvertingBiology · 2024Review
- Hyperplastic ovarian stromal cells express genes associated to tumor progression: a case study.BMC veterinary research · 2024Article
- Areca nut-induced metabolic reprogramming and M2 differentiation promote OPMD malignant transformation.Journal of experimental & clinical cancer research : CR · 2024Article
- Structural analysis of peptide binding to integrins for cancer detection and treatment.Biophysical reviews · 2023Review
- VCAM-1 complements CA-125 in detecting recurrent ovarian cancer.Clinical proteomics · 2023Article
- Human Antibody VMolecular pharmaceutics · 2023Article
- Cancer stem cells markers in ovarian cancer: Clinical and therapeutic significance (Review).Oncology letters · 2022Review
- An immune-related gene prognostic risk index for pancreatic adenocarcinoma.Frontiers in immunology · 2022Article
- Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer.Scientific reports · 2020Article
- VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer.Translational oncology · 2020Article
- VCAM1 Promotes Tumor Cell Invasion and Metastasis by Inducing EMT and Transendothelial Migration in Colorectal Cancer.Frontiers in oncology · 2020Article
- In Vivo Assessment of VCAM-1 Expression by SPECT/CT Imaging in Mice Models of Human Triple Negative Breast Cancer.Cancers · 2019Article
- Nutrient Deprivation Modulates the Metastatic Potential of Breast Cancer Cells.Reports of biochemistry & molecular biology · 2019Article
- Human epithelial ovarian cancer cells expressing CD105, CD44 and CD106 surface markers exhibit increased invasive capacity and drug resistance.Oncology letters · 2019Article
- Signaling Complexity Measured by Shannon Entropy and Its Application in Personalized Medicine.Frontiers in genetics · 2019Article
- Bufalin inhibits glycolysis-induced cell growth and proliferation through the suppression of Integrin β2/FAK signaling pathway in ovarian cancer.American journal of cancer research · 2018Article
- LAMP1 expression is associated with poor prognosis in breast cancer.Oncology letters · 2017Article
- High KIF2A expression predicts unfavorable prognosis in diffuse large B cell lymphoma.Annals of hematology · 2017Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
High expression of vascular cell adhesion molecule 1 (VCAM1) has been shown to be associated with several cancers although its role in ovarian cancer development is largely undefined. The purpose of this study is to investigate its role in ovarian cancer using the epithelial cells and ovarian cancer cell lines and correlate its expression with clinicopathologic parameters in ovarian cancer patients. VCAM1 expression was examined via immunohistochemical staining of 251 high grade serous carcinoma samples using tissue microarray. The expression of VCAM1 was silenced in RAS-transformed ovarian epithelial cell lines and two high grade ovarian cancer cell lines. Cell migration was analyzed in vitro and effect on tumor growth was analyzed in nude mice. High VCAM1 expression was found to be was related with response to surgery and chemotherapy drugs (P = 0.025) and elder age at diagnosis (P = 0.008). Cox regression multivariable analysis showed that VCAM1 expression in tumor cells was an independent prognostic factor. Ovarian cancer cells with VCAM1 overexpression, compared with corresponding control cells, had increased cell migration and enhanced growth of xenograft tumors in mice. Our data provide strong evidence that VCAM1 plays an important role in ovarian tumor growth, and it may be used as a prognostic factor and novel therapeutic target for ovarian cancer.
Indexed as
Identifiers
23634244PMC3633976W48702940What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.